Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for alleged violations of the Securities Exchange Act, specifically for making false and misleading statements regarding its financial reporting [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from July 18, 2024, to November 12, 2025, with a deadline for lead plaintiff appointments set for March 9, 2026 [2]. - The complaint alleges that Ardent Health utilized a 180-day cliff on accounts receivable, allowing the company to report inflated amounts and delay loss recognition, rendering its public statements materially misleading [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3].

Core Viewpoint - The Schall Law Firm is investigating Oracle Corporation for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Oracle issued false or misleading statements and failed to disclose critical information to investors [2]. - A report indicated that Oracle announced a $300 billion, five-year deal with OpenAI in September, followed by raising $18 billion through bonds and notes two weeks later, and an additional $38 billion seven weeks after the initial offering to fund data centers for the same agreement [2]. - Bondholders from the initial $18 billion raise claim they should have been informed about the company's need to return to capital markets for such a large raise shortly after [2]. Group 2: Market Reaction - Following the news of the investigation and the bondholder claims, Oracle's shares experienced a decline of nearly 4.3% [2].

Core Viewpoint - Block & Leviton is investigating Aquestive Therapeutics, Inc. for potential securities law violations following a significant drop in its stock price due to FDA deficiencies in its drug application [1][2]. Group 1: Company Overview - Shares of Aquestive Therapeutics fell more than 40% on January 9, 2026, after the company disclosed that the FDA identified deficiencies in its new drug application for Anaphylm, raising the risk of delayed approval [2]. - Block & Leviton is investigating the company's prior disclosures to determine if there were any violations of securities laws [4]. Group 2: Investor Eligibility - Any investor who purchased common stock of Aquestive Therapeutics and has experienced a decline in their investment may be eligible to participate in the investigation, regardless of whether they have sold their shares [3]. Group 3: Legal Actions and Support - Block & Leviton is prepared to file an action to recover losses on behalf of investors who have lost money due to the company's disclosures [4]. - Investors who have non-public information about Aquestive Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]. Group 4: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - Corcept Therapeutics Inc. is under investigation by Block & Leviton for potential securities law violations following a significant drop in its stock price after receiving a Complete Response Letter from the FDA regarding its drug relacorilant [1][2]. Group 1: Company Overview - Corcept Therapeutics' shares fell more than 50% on December 31, 2025, due to the FDA's Complete Response Letter indicating the need for additional evidence of effectiveness for relacorilant [2]. - The company is facing scrutiny as investors who have lost money in their investments are encouraged to contact Block & Leviton for potential recovery options [1][3]. Group 2: Legal Investigation - Block & Leviton is investigating whether Corcept Therapeutics committed securities law violations and may file an action to recover losses for affected investors [4]. - Investors who purchased Corcept Therapeutics common stock and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they sold their shares [3]. Group 3: Whistleblower Information - Individuals with non-public information about Corcept Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 4: Firm's Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - The Schall Law Firm is investigating Nutanix, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Financial Performance - Nutanix reported Q1 2026 financial results on November 25, 2025, with revenue at the lower end of its prior guidance [2]. - The company attributed the revenue shortfall to a "revenue shift from Q1 to future periods" and customer demand for flexible start dates [2]. - Following the announcement, Nutanix's shares dropped by 17.8% the next day [2]. Legal Investigation - The investigation by the Schall Law Firm focuses on whether Nutanix misled investors regarding its financial performance and future projections [2]. - Shareholders who experienced losses are encouraged to participate in the investigation and can contact the Schall Law Firm for more information [3].

Core Viewpoint - Block & Leviton is investigating Aquestive Therapeutics, Inc. for potential securities law violations following a significant drop in the company's stock price due to FDA deficiencies in its new drug application for Anaphylm [1][2]. Group 1: Company Overview - Shares of Aquestive Therapeutics fell more than 40% on January 9, 2026, after the company disclosed that the FDA identified deficiencies in its new drug application for Anaphylm, raising the risk of delayed approval [2]. - Block & Leviton is investigating the company's prior disclosures to determine if there were any securities law violations [4]. Group 2: Investor Information - Any investor who purchased Aquestive Therapeutics common stock and has experienced a decline in their investment may be eligible to recover losses, regardless of whether they have sold their shares [3]. - Investors are encouraged to contact Block & Leviton for more information on how to proceed with potential recovery [5]. Group 3: Legal Action and Whistleblower Information - Block & Leviton may file an action to recover losses on behalf of investors who have lost money due to the company's disclosures [4]. - Whistleblowers with non-public information about Aquestive Therapeutics are encouraged to assist in the investigation or report to the SEC, with potential rewards of up to 30% of any successful recovery [6]. Group 4: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Telix Pharmaceuticals Ltd. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1][3]. Group 1: Allegations - The complaint alleges that during the class period from February 21, 2025, to August 28, 2025, Telix Pharmaceuticals materially overstated its progress with prostate cancer therapeutic candidates [3]. - It is claimed that the company also overstated the quality of its supply chain and partners, leading to false and misleading statements about its business operations and prospects [3]. Group 2: Class Action Details - Shareholders who purchased shares of TLX during the class period are encouraged to register for the class action, with a deadline set for January 9, 2026 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Integer Holdings Corporation (NYSE: ITGR) is facing allegations of issuing materially false and misleading statements regarding its competitive position and sales performance in the electrophysiology manufacturing market during the class period from July 25, 2024, to October 22, 2025 [1]. Group 1: Allegations - The complaint alleges that Integer overstated its competitive position within the growing electrophysiology manufacturing market [1]. - Despite claims of strong visibility into customer demand, Integer was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [1]. - Integer mischaracterized its electrophysiology devices as a long-term growth driver for the Company's cardio & vascular segment [1]. - As a result of these issues, the positive statements made by defendants about the Company's business, operations, and prospects were materially false and misleading [1]. Group 2: Class Action Details - Shareholders who purchased shares of ITGR during the specified class period are encouraged to contact the Gross Law Firm regarding possible lead plaintiff appointment [1]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is February 9, 2026 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [2].

Core Viewpoint - Apogee Enterprises, Inc. is under investigation for potential securities law violations following a significant drop in its stock price after disappointing quarterly results and a lowered full-year outlook [2][4]. Group 1: Company Performance - Apogee Enterprises' shares fell over 13% in intraday trading after the company reported quarterly results that missed analyst expectations [2]. - The company cited weaker demand and margin pressure in its Architectural Glass segment as reasons for lowering its full-year outlook [2]. Group 2: Management Changes - Apogee disclosed the resignation of its Chief Financial Officer, Matthew Osberg, effective January 16, 2026 [2]. Group 3: Legal Investigation - Block & Leviton is investigating whether Apogee committed securities law violations and may file an action to recover losses for affected investors [4]. - Investors who have lost money on their Apogee investments are encouraged to contact Block & Leviton for potential recovery options [5].

Core Viewpoint - The Schall Law Firm is investigating claims against Temenos AG for potential violations of securities laws, focusing on whether the company made false or misleading statements or failed to disclose important information to investors [1]. Group 1 - The investigation is aimed at protecting the rights of investors who may have suffered losses due to the company's actions [1]. - Temenos AG is traded on the OTC market under the ticker symbol TMSNY [1]. Group 2 - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [2]. - Investors are encouraged to contact the firm for a free discussion regarding their rights [2].